MOUNTAIN VIEW, Calif.– Boomerang Medical, Inc., a women-led bioelectronic medicine company, announced it has raised $20 million in Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. The funds will support BOOM-IBD2, the first pivotal clinical trial evaluating an implantable neuromodulation device for inflammatory bowel disease (IBD), with an initial focus on ulcerative colitis. The trial is now enrolling patients at leading U.S. medical centers (NCT06571669).
Ulcerative colitis, the most common form of IBD, is a chronic autoimmune disease that affects millions in the U.S. and Europe. Despite its prevalence, there are currently no device-based therapeutic options. Boomerang’s approach uses sacral neuromodulation—a small implanted device delivering gentle nerve stimulation—to reduce symptom burden. The therapy has a long-established safety record in other conditions, with more than 500,000 procedures performed worldwide. A prior 40-patient feasibility study in Crohn’s disease and ulcerative colitis informed the design of the pivotal trial.
“Ulcerative colitis patients struggle with symptoms that profoundly affect their daily lives,” said Heather Simonsen, CEO of Boomerang Medical. “Our pivotal trial asks a critical question: can this therapy meaningfully reduce symptom burden and improve quality of life? With strong investor support, we are working to deliver that answer for patients and their physicians.”
Tom Shehab, M.D., gastroenterologist, Managing Partner at Arboretum Ventures, and Boomerang board member, added: “There is a significant unmet need for new approaches in ulcerative colitis. We are impressed with Boomerang’s team and their rigorous clinical strategy. This financing positions them well to complete their pivotal trial and advance this promising therapy.”
Boomerang Medical was recently recognized as the Crohn’s & Colitis Foundation’s “Emerging Leader in IBD,” becoming the first medical device company to earn the honor.
